Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6856 AL 6870

Bilateral deep brain stimulation of the fornix for Alzheimer's disease: surgical safety in the ADvance trial

Ponce FA, Asaad WF, Foote KD, Anderson WS, Rees Cosgrove G, Baltuch GH, Beasley K, Reymers DE, Oh ES, Targum SD, Smith GS, Lyketsos CG, Lozano AM; ADvance Research Group.

J Neurosurg. 2016 Jul;125(1):75-84. doi: 10.3171/2015.6.JNS15716. Epub 2015 Dec 18.

Deep Assessment: A Novel Framework for Improving the Care of People with Very Advanced Alzheimer's Disease

Lyons G, Arthur-Kelly M, Eidels A, Mavratzakis A.

Biomed Res Int. 2015;2015:749451. doi: 10.1155/2015/749451. Epub 2015 Nov 24.

Flavonoid-based therapies in the early management of neurodegenerative diseases

Solanki I, Parihar P, Mansuri ML, Parihar MS.

Adv Nutr. 2015 Jan 15;6(1):64-72. doi: 10.3945/an.114.007500. Print 2015 Jan.

Nonpeptide neurotrophic agents useful in the treatment of neurodegenerative diseases such as Alzheimer's disease

Akagi M, Matsui N, Akae H, Hirashima N, Fukuishi N, Fukuyama Y, Akagi R.

J Pharmacol Sci. 2015 Feb;127(2):155-63. doi: 10.1016/j.jphs.2014.12.015. Epub 2015 Jan 13.

Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis

Beauchet O, Launay CP, Montero-Odasso M, Annweiler C, Allali G.

Curr Alzheimer Res. 2015;12(8):761-71. doi: 10.2174/1567205012666150710111341.

Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis

Beauchet O, Launay CP, Allali G, Annweiler C.

CNS Drugs. 2014 Jun;28(6):513-8. doi: 10.1007/s40263-014-0170-6.

Alzheimer disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies

Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzenadah AM, Kamal W, Kamal MA, Tan Y, Qu X, Reale M.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):467-77. doi: 10.2174/18715273113126660153.

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

Hölscher C.

Biochem Soc Trans. 2014 Apr;42(2):593-9. doi: 10.1042/BST20140016.

The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis

Killin LO, Russ TC, Starr JM, Abrahams S, Della Sala S.

BMJ Open. 2014 Apr 7;4(4):e004083. doi: 10.1136/bmjopen-2013-004083.

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders

Forlenza OV, De-Paula VJ, Diniz BS.

ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6.

Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology

Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T, Shill H, Adler C, Sabbagh M, Villa S, Tembe W, Craig D, Van Keuren-Jensen K.

PLoS One. 2014 May 5;9(5):e94839. doi: 10.1371/journal.pone.0094839. eCollection 2014.

Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies

Broadstock M, Ballard C, Corbett A.

Expert Opin Pharmacother. 2014 Sep;15(13):1797-810. doi: 10.1517/14656566.2014.936848. Epub 2014 Jul 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias